BPG is committed to discovery and dissemination of knowledge
Review
Copyright: ©Author(s) 2026.
World J Gastroenterol. Jan 21, 2027; 33(3): 124080
Published online Jan 21, 2027. doi: 10.3748/wjg.124080
Table 1 Published clinical evidence on liver transplantation for intrahepatic cholangiocarcinoma: Patient selection, treatment strategies, and outcomes
Ref.
Year
n
Incidental/known
1-year OS
3-year OS
1-year DFS
3-year DFS
Recurr-ence
Neoadjuvant treatment
Adjuvant treatment
LRT
Jeong et al[26]202615Incidental73.353.3NRNRYes (11)NoneCT after recurrenceNR
Giguet et al[27]20266Known10010010044.41Yes (3)GemCis (4); GemCis + durvalumab (1); LV5FU2 + Cis (1)NoneSIRT/Y-90 (6)
Asanuma et al[28]20261Incidental100NR100NRNoneNoneNoneNone
Yaqub et al[29]20255KnownNRNRNRNRYes (2)Gem-based CT (5); Erdafitinib (1)NoneSIRT/Y-90 (1)
Wei et al[30]2025124Known68.235.551.029.3Yes (50)Neoadjuvant therapy (26; mainly GemCis CT)NRNR
Semaan et al[31]202526Known96.082.770.856.3Yes (11)Systemic CT (23/26: Gem 22, platinum 20, 5-FU 11, TKI 3)NoneTARE (5), radiation (8), TACE (1), ablation (1)
Ma et al[32]202512Incidental 75.066.766.758.3NRNone2/12; type NRPre-LT treatment 3/12; type NR
Liguori et al[33]20251Incidental 100NR100NRNoneNoneCapNone
De Abreu Neto et al[34]20252IncidentalNRNRNRNRNRNRNRNR
Byrne et al[35]20251Known100NR100NRNoneGemCis; Gem; maintenance; pemigatinibPemigatinibTARE/Y-90
Baimas-George et al[36]20251KnownNRNRNRNRNRRTNRNone
Zhu et al[37]202440MixedNRNRNRNRNRNRNRNR
Teixeira et al[38]20241Known100NR100NRNoneGemCis; Gem maintenance; FOLFOX; 5-FU/LVNRTARE/Y-90 × 3
Rodríguez-Espinosa et al[39]20241Incidental 1000NR0Yes (1)NRNRNone
Remiszewski et al[40]20242Incidental100NR100NRNoneNoneNoneNone
Maspero et al[22]20244Known100100100100NoneGemCis (4); pemigatinib (1)NoneTARE/Y-90 (4)
Howell et al[41]2024153MixedNRNRNRNRNRCT (84/153; regimen NR)CT (17/153; regimen NR)NR
Fernandes et al[42]20242Known100NR100NRNoneGemCis (2); durvalumab (1)NRNone
Bednarsch et al[43]20241Known100NR100NRNoneGemCisNoneNone
Andraus et al[16]20241Known100NR100NRNoneGemCis; maintenance GemCisNRGemOX/HAIC
Schwenk et al[44]20234Incidental75757575NoneNRNRNR
Huang et al[45]2023113Mixed82.460.3NRNRNRCT (62; regimen NR); radiation (30; modality NR)NRNR
Garcia-Moreno et al[46]20232IncidentalNRNRNRNRNoneNRNoneNR
Endo et al[47]202354MixedNR60.52NRNRNRNRNRNR
Safdar et al[48]202240Incidental82.168.73NRNRNRNRCap (1); Doxorubicin (9)3TACE (1)
Rauchfuß et al[49]20222Known (1)100100100100NoneGemCis (1)NRSIRT (1)
McMillan et al[23]202218Known100717052Yes (7)GemCis (16); GemCap (1); FOLFOX (1); XRT (4)GemCap (6); Cap (2); Gem (1); olaparib (1); ivosidenib (1); Gem + nab-paclitaxel (1); 5-FU (1)TARE/Y-90 (3); TACE (1); IRE/RFA(1)
Lee et al[50]202262Mixed88.972.9NR4NRNRNRNRNR
Kim et al[51]202266MixedNS36.15NRNRNRCT (25; regimen NR)CT (40; regimen NR)NR
Ito et al[52]202230Mixed80637346NRCT or LRT alone (6); CT + LRT (4); exact modality NR20; regimen NRTACE/RFA; exact iCCA-specific n NR
Brandão et al[53]20228Incidental37.53737.538.0NRNoneNRTACE (8)
Abdelrahim et al[55]20227Known10068.685.771.4Yes (2)GemCis (2), Cap (3), FOLFIRI (2)NRNone
Abdelrahim et al[54]20227Known10075.010085.7Yes (1)GemCis (7)NRNR
Ren et al[56]202128MixedNRNR6NRNR6Yes (15)GemCis-based CT; exact n NRNRTACE/ablation (21; exact split NR)
Hue et al[58]202174Mixed89.453.07NRNRNRCT (52); RT (39); regimen NRCT (3); regimen NRNR
Hara et al[59]202119Incidental79.063.0879.045.08Yes (10)NoneGem-based CT/TACE/RFA after recurrence TACE (1)
Gruttadauria et al[60]20214Incidental (3)NRNRNRNRNRNoneNRSIRT (1)
Gruttadauria et al[61]20216Incidental (5)NRNRNRNRNRCT (1; regimen NR)NRTARE (1); TACE (2); MWA (1)
Ren et al[57]202049MixedNRNRNRNRYes (23)GemCis-based CT; exact n NRGemCis; timing NRTACE (18); ablation (8); TACE + ablation (4)
Krasnodębski et al[62]20208Incidental75.037.571.428.6NRNRNRNR
Herrero Torres et al[63]20201Incidental100100100100NoneNoneNRNone
Hafeez Bhatti et al[64]20209IncidentalNRNRNR63.0NRNoneNRTACE/RFA; exact iCCA-specific n NR
De Martin et al[17]202024IncidentalNRNRNRNRNRNRNRNR
Mitra et al[65]20181IncidentalNRNRNRNRNoneNoneNRNone
Lunsford et al[21]20186Known 10083.35050Yes (3)GemCis (6); Erlotinib-containing therapy (3); Gem (3); GemCap (2); Cap + SBRT (1); 5-FU + Gem (1); FOLFIRI (1)Gem (4); Cape (1); GemCap (1)None
Lee et al[66]201817Incidental81.3NR9NRNRYes (5)NoneNRTACE (13); RFA (1)
Jung et al[67]20178Incidental62.562.562.562.5Yes (5)NoneCT after recurrence (1; regimen NR)TACE (6)
Gupta et al[68]20173Incidental NRNRNRNRNRNRNRNR
Elshamy et al[69]20174IncidentalNRNRNRNRYes (1)NoneCT after recurrence (1; regimen NR)TACE (2)
Takahashi et al[70]20169IncidentalNRNRNRNRNRNoneNoneTACE/RFA; exact pure iCCA n NR
Serra et al[71]20161Incidental100NR00Yes (1)NoneNoneNone
Sapisochin et al[24]201615Mixed93.084.093.082.0Yes (2)NRNRTACE (3); ablation (2); TACE + ablation (1); other (1)
Sapisochin et al[24]201633Mixed79.050.070.053.0Yes (17)NRNRTACE (9); ablation (6); TACE + ablation (2); other (1)
Rayar et al[72]20161Known100100100100NoneLV5FU2-Cis; EBRTNoneTARE Y-90
Lindnér et al[73]20155MixedNR60.0NRNRNRNRNRNR
Facciuto et al[74]20157MixedNRNRNRNRYes (2)NRNRNR
Sperling et al[75]20141Incidental100100100100Yes (1)NoneNonePre-LT TACE; SIRT after recurrence
Sapisochin et al[20]201418IncidentalNRNRNRNRNRNoneNRNR
Sapisochin et al[25]201429NR79.061.089.071.0Yes (7)NoneNRTACE (8); RFA (3); PEI (2)
Patkowski et al[76]20146IncidentalNR25.0NR0Yes (6)NoneGem/5-FU + doxorubicin + mitomycinNR
Vallin et al[77]20134Incidental75.075.075.075.0Yes (1)NoneNoneNR
Fukuda et al[78]20131Incidental0000Yes (1)NoneNone; GemCis after recurrenceNone
Vera et al[79]20121Incidental100NR00Yes (1)NoneGemOX + RT for pain after recurrenceNone
Hrehoreţ et al[80]20121Incidental100NR100NRNoneNoneGemOXNone
Sapisochin et al[81]20114IncidentalNRNRNRNRNRNoneNoneLRT (4; modality for pure iCCA NR)
Hu and Yan[82]201120Incidental84.232.755.628.8Yes (12)Yes; type/count NRNRNR
Hong et al[83]201125KnownNRNRNRNRNRCT ± RT (9)CT ± RT (16)NR
Fu et al[84]10201111Mixed50.550.551.951.9Yes (5)3D-CRT (1)NRTACE + PEI (1); TACE (1); RFA (1)
Friman et al[85]201133MixedNRNRNRNRNRNRNRNR
Ali et al[86]20112IncidentalNRNRNRNRYes (2)NoneNoneNone
Table 2 Comparative overview of the two main liver transplantation pathways for intrahepatic cholangiocarcinoma
Feature
Very early/small iCCA in cirrhosis
Unresectable liver-limited iCCA: Neoadjuvant selection pathway
Typical liver backgroundCirrhosis/end-stage liver diseaseOften non-cirrhotic or compensated chronic liver disease
Tumor stageVery earlyLocally advanced but liver-limited
Classical size thresholdSingle tumor ≤ 2 cmNo universally accepted size threshold
Expanded threshold under discussionSelected cirrhotic patients with solitary tumors ≤ 3 cm under consensus/guidance frameworksSize less important than biological response
DiagnosisOften incidental or HCC-mimicking; biopsy should be pursued when iCCA is intentionally considered for LTBiopsy-proven iCCA required
Main rationale for LTTreats both tumor and underlying liver disease when resection is unsafeProvides a curative-intent option for unresectable liver-limited disease
Required biology testObservation/stability with absence of growth or spreadAt least 6 months of radiographic stability or response after neoadjuvant therapy
Neoadjuvant/bridging therapyBridging may be considered depending on waiting timeSystemic chemotherapy with or without selected LRT
Mandatory exclusionsExtrahepatic disease, regional lymph node metastasis, peritoneal disease, macrovascular tumor thrombus/definite vascular invasionExtrahepatic disease, regional lymph node metastasis, peritoneal disease, macrovascular tumor thrombus/definite vascular invasion, progression on therapy
Evidence baseRetrospective explant-based studies; meta-analysis; consensus/guidance extensionSmall prospective protocol series, mature single-center cohort, and intention-to-treat downstaging studies
Current statusNarrowly selected potential indicationInvestigational/protocol-driven indication
Table 3 Factors supporting or arguing against consideration of liver transplantation in intrahepatic cholangiocarcinoma
Domain
Factors supporting LT consideration
Factors not supporting LT consideration
Disease extentLiver-limited diseaseExtrahepatic metastasis or peritoneal disease
Nodal statusRadiologically and/or pathologically negative nodesSuspicious nodes requiring sampling; confirmed regional lymph node metastasis
Tumor burdenSolitary small tumor; limited intrahepatic burden; controlled multifocality within protocolDiffuse uncontrolled multifocal bilobar disease
Cirrhosis settingVery early iCCA in cirrhosis; unsafe resection due to portal hypertension or poor liver reserveAdequate liver reserve and safely resectable tumor favor resection rather than LT
Response to therapyDurable stability or response for ≥ 6 months after neoadjuvant therapyProgression during systemic therapy or LRT
Tumor markersStable or decreasing CA19-9 and CEA kinetics interpreted in clinical contextClinically concerning rise in CA19-9 and CEA despite treatment
Vascular involvementVascular proximity or encasement without tumor thrombus or intimal invasionMacrovascular tumor thrombus or definite intimal vascular invasion
BiologyLong observation without progressionRapid interval growth or early progression
HistologyWell-differentiated or moderately differentiated tumorPoorly differentiated tumor
Surgical stagingNegative peritoneal assessment and nodal sampling when performedPositive peritoneal assessment, positive peritoneal washing, or positive regional lymph nodes
Molecular profilePotentially targetable alteration; no validated high-risk exclusion signalPotentially adverse molecular alterations as investigational risk signals, not stand-alone exclusion criteria
Patient factorsGood performance status; transplant fitnessFrailty, poor performance status, uncontrolled comorbidity


Write to the Help Desk